LENZ Therapeutics, Inc. fell 11.2% on Friday, November 20, 2026, on 951,160 shares. No headline about LENZ came out that day or the day before in the news feeds we follow, so the move may come from news we don't track, the sector or trading alone.
LENZ Therapeutics, Inc. (LENZ:NASDAQ) closed at $2.97 on November 20, 2026, down 11.23% on the day. The stock trades 90.8% below its 52-week high of $32.13 and 5.9% above its 52-week low of $2.80. Over the past year, it lost 90.7%. LENZ Therapeutics, Inc. is part of the Health Care sector.
In 252 trading sessions since November 20, 2025, LENZ closed higher on 105 days (42%). Its best day was November 9, 2026 (+22.57%) and its worst was December 12, 2025 (-25.96%). The stock moved 10% or more in a single session 15 times. It opened at least 5% above the previous day's high 1 time.
Graphite Bio Inc is a clinical-stage gene-editing company harnessing gene integration to develop a new class of therapies to cure serious and life-threatening diseases. Its gene-editing platform allows to precisely correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined, safe locations. Its lead product candidate GPH101 is a differentiated approach with the potential to directly correct the mutation that causes sickle cell disease (SCD) and restore normal adult hemoglobin (HgbA) expression. All of the company's long-lived assets are based in the United States.
Find more stocks like LENZ with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.